Dare Bioscience (DARE) Files 8-K Report

Ticker: DARE · Form: 8-K · Filed: Sep 2, 2025 · CIK: 1401914

Sentiment: neutral

Topics: listing, regulatory

Related Tickers: DARE

TL;DR

DARE's common stock is listed on Nasdaq. Nothing else new.

AI Summary

On September 2, 2025, Dare Bioscience, Inc. (DARE) filed an 8-K report. The filing indicates that the company's common stock is registered on the Nasdaq Capital Market under the trading symbol DARE. No other specific financial transactions or material events are detailed in the provided excerpt.

Why It Matters

This filing confirms the listing of Dare Bioscience's common stock on the Nasdaq Capital Market, which is essential information for investors and market participants tracking the company.

Risk Assessment

Risk Level: low — The provided excerpt is a standard 8-K filing that primarily confirms listing information and does not contain significant new financial or operational details that would indicate high risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report current information as required by the Securities Exchange Act of 1934, specifically confirming the company's registration and stock listing details.

What is the trading symbol for Dare Bioscience, Inc. common stock?

The trading symbol for Dare Bioscience, Inc. common stock is DARE.

On which exchange is Dare Bioscience, Inc. common stock registered?

Dare Bioscience, Inc. common stock is registered on the Nasdaq Capital Market.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported in this filing is September 2, 2025.

Does this filing indicate any new financial transactions or material events?

Based on the provided excerpt, this filing does not detail any new specific financial transactions or material events beyond confirming the company's listing information.

Filing Stats: 606 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-09-02 08:00:48

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DAR BIOSCIENCE, INC. Dated: September 2, 2025 By: /s/ Sabrina Martucci Johnson Name: Sabrina Martucci Johnson Title: President and Chief Executive Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing